OBI Pharma, Inc.

Equities

4174

TW0004174008

Biotechnology & Medical Research

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-05-27 pm EDT			5-day change	1st Jan Change
59.1 ^TWD	+0.85%		-2.80%	-14.84%

May. 10	Obi Pharma, Inc. Announces the Termination of License Agreement with Odeon for the Rights of Obi-999 and Obi-833 in China, Hong Kong and Macau	CI
Mar. 26	OBI Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

OBI Pharma, Inc. Announces Director Changes

June 27, 2022 at 04:58 am EDT

OBI Pharma, Inc. announced director changes. Name of the previous position holder: Director Michael Chang, Representative of Yi Tai Investment Co. Ltd. Director Tamon Tseng, Representative of Yi Tai Investment Co.

Ltd. Director Yun Yen, Representative of Sheng Cheng Investment Co. Ltd. Director Frank Chen, Representative of Sheng Cheng Investment Co. Ltd. Independent Director Jerry Fong, Independent Director Taychang Wang, Independent Director Howard Lee.

name of the new position holder: Director Michael Chang Director Tamon Tseng, Representative of Yi Tai Investment Co. Ltd. Director Yun Yen, Representative of Sheng Cheng Investment Co. Ltd. Director Frank Chen, Representative of Sheng Cheng Investment Co.

Ltd. Independent Director Howard Lee Independent Director Ming-Chin Chen Independent Director Chin-Ting Chiu. Resume of the new position holder: Director Michael Chang /Chairman of the Board and CEO, OBI Pharma Inc. Director Tamon Tseng, Representative of Yi Tai Investment Co., Ltd/Special Assistant to Legal Division, Ruentex Group Director Yun Yen, Representative of Sheng Cheng Investment Co. Ltd./Chairman of the Board, Tanvex BioPharma, Inc. Director Frank Chen, Representative of Sheng Cheng Investment Co.

Ltd./Vice President, Investment Management Department and Special Assistant to President, Ruentex Group Independent Director Howard Lee /Chairman of the Board, TAHO Pharmaceuticals Ltd. Independent Director Ming-Chin Chen /Accounting Professor, National Chengchi University Independent Director Chin-Ting Chiu /Member of Mediation Committee, Securities and Futures Investors Protection Center. Date of occurrence of the change: June 27, 2022.

Latest news about OBI Pharma, Inc.

Obi Pharma, Inc. Announces the Termination of License Agreement with Odeon for the Rights of Obi-999 and Obi-833 in China, Hong Kong and Macau	May. 10	CI
OBI Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
Obi Pharma, Inc. Announces the Termination of Obi-3424-001 Trial While Continuing the Collaboration Of obi-3424 with Partners	Mar. 11	CI
OBI Pharma, Inc. Announces Adagloxad Simolenin (OBI-822) Receives Positive 1st Interim Analysis Recommendation, Recommending the Continues of the Phase III TNBC Trial	Jan. 31	CI
OBI Pharma, Inc. Announces OBI-992 TROP2 ADC Has Been Granted by US FDA to Proceed to Phase I/II Human Clinical Trial	Jan. 03	CI
OBI Pharma, Inc. Announces Resignation of Yun Yen as Chairperson and Director, Effective December 29, 2023	Dec. 20	CI
Obi Pharma, Inc. Files the Application of Phase I/II Human Clinical Trial for OBI-992 TROP2 ADC to US FDA	Dec. 01	CI
OBI Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
OBI Pharma, Inc. Announces Head Office Address Change	Nov. 06	CI
OBI Pharma, Inc. Announces Internal Audit Officer Changes	Nov. 06	CI
OBI Pharma, Inc. Announces CFO Changes	Nov. 06	CI
OBI Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
OBI Pharma, Inc. Announces Executive Changes	23-08-07	CI
OBI Pharma, Inc. Announces Appointment of Yun Yen as the Chairman	23-06-27	CI
OBI Pharma, Inc. Announces Appointment of Yun Yen as Natural-Person Director	23-06-27	CI
OBI Pharma, Inc. Announces COVID-19 Vaccine, BCVax, Has Been Granted by TFDA to Proceed to Phase I Clinical Trial	23-06-02	CI
OBI Pharma Appoints Heidi Wang as Chief Executive Officer	23-06-02	CI
OBI Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
OBI Pharma, Inc. Files the Application of Phase I Human Clinical Trial for COVID-19 Vaccine, BCVax, to TfDA	23-03-31	CI
OBI Pharma, Inc.(TPEX:4174) dropped from FTSE All-World Index	23-03-20	CI
OBI Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-15	CI
OBI Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-15	CI
Obi Pharma, Inc. Files Application for Phase II Human Clinical Trial of First-In-Class Novel Prodrug, Obi-3424, to TFDA	23-02-02	CI
OBI Pharma, Inc. Announces Demise of Chairman of the Board, Michael Chang	22-12-29	CI
United States Patent and Trademark Office Grants Patent for OBI-866 Immunogenic/Therapeutic Glycan Compositions and Uses Thereof	22-12-23	CI

Chart OBI Pharma, Inc.

Duration

Period

More charts

Company Profile

OBI Pharma, Inc. is a Taiwan-based company principally engaged in the development of new pharmaceuticals. The Company mainly operates its businesses through the research and development of novel cancer and infectious disease therapies. It also develops next generation active immunotherapies to treat cancers, including lung, prostate, pancreatic, stomach and ovarian cancers. It is engaged in the development of OBI-822 (formerly OPT-822/821), an active immunotherapy new drug for metastatic breast cancer; the research and development of therapeutic vaccine OBI-833 for the treatment of new generation of cancers, as well as the development of cancer testing reagent OBI-868.

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
OBI PHARMA, INC.	-14.84%	417M
MODERNA, INC.	+54.05%	63.85B
IQVIA HOLDINGS INC.	-2.02%	41.83B
LONZA GROUP AG	+40.01%	40.47B
CELLTRION, INC.	-10.22%	27.17B
ICON PUBLIC LIMITED COMPANY	+13.42%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-21.60%	18.69B
BIO-TECHNE CORPORATION	+2.89%	12.73B
UNITED THERAPEUTICS CORPORATION	+22.40%	12.11B
MEDPACE HOLDINGS, INC.	+27.49%	12.07B

Other Biotechnology & Medical Research